
By Lauren Giella
Senior Reporter
0
Share
Newsweek is a Trust Project member
See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.
Oracle Health and Life Sciences Executive Vice President and General Manager Seema Verma said Tuesday that artificial intelligence may be the key to closing the gap between administering quality health care and conducting critical medical research.
During a panel at the Summit on the Future of Rural Health in Sioux Falls, South Dakota, Verma joined Newsweek Health Care Editor Alexis Kayser in a discussion about how AI technology, like the latest offers from Oracle, can ease provider burden and increase participation when conducting clinical trials.
Read More on Health
Why It Matters
Clinical trials and medical research have traditionally been conducted at academic facilities, typically in urban areas. With rising costs and labor shortages, these institutions are struggling to keep up. That's where artificial intelligence can help.
"When we talk to some of the academic research institutions, they say, 'We don't have the capacity to do any more [clinical trials], we don't have enough nurses, we don't have enough doctors, we don't have enough people to do more clinical trials," Verma said. "And so if we can automate some of this work, there's a capacity to do even more clinical trials and make it easier, so that it doesn't just have to happen at an academic research center, you know, across the board."
Verma said pharmaceutical companies want to do more trials with a more diverse population. And rural health systems want to participate in clinical trials to increase revenue and the quality of care they provide, but often don't have the resources.
With AI, Verma said, Oracle is making it easier for these health systems to participate without having to hire more people or increase costs through automation.
What to Know
If a health system wants to participate in clinical trials, Verma said, it has to make the data available to use and do the matching to connect the right patient with the right trial.
She said AI has the potential to ease the burden placed on clinicians while increasing the access and quality of care.
For example, people usually have to physically retype data from electronic health records (EHR) into a different system for clinical trials, called the electronic data capture. AI, Verma said, can help health systems integrate that data automatically, eliminating the manual burden and allowing clinicians to do other things.
Oracle Health EHR is an AI-powered system that helps automate tasks to alleviate labor burdens and lower costs. This new technology can also help physicians determine which patients are eligible for certain clinical trials
"So the idea is that any provider all over the world potentially participates in a clinical trial," she said.
With this new technology, Verma said rural health systems won't have to change too much about their existing workflows, they just have to ensure the data they have is complete and interoperable.
"For rural providers, the data interoperability is foundational, because if [patients] are going to be receiving remote care, virtual care, home care, the data has to move in real time," she said. "You can't have data that comes two or three days later. And the same thing with the AI; the AI is only as good as the data underneath it."
Verma said the expectation with AI technology is that it will drive real value. For AI technology to scale clinical trials, she said, it has to reduce the amount of manual effort.
"[AI] has to increase access to care, it has to reduce cost, it has to improve quality," she said. "And in order to do that, I think it's not enough to just say, 'We're going to use this AI agent or that AI agent,' we have to really think about the impact on all of our processes."
What Happens Next
Looking ahead, Verma said many pharmaceutical companies want to increase access to clinical trials to bring them out of academic settings and allow for more diversity in participation.
Decentralizing these trials means utilizing the virtual and at-home care innovations that rural health systems have been using for years.
"We think about the clinical trial in the traditional sense of people coming into an academic health center. That doesn't have to be the case anymore," she said. "The rural providers, because they've already sort of broken ground on delivering care differently and in new ways using technology, those same models can be brought to trials."
Regulating these at-home trials to ensure the integrity of the data will be a challenge, but Verma said the value of increasing participation in trials will make those measures worthwhile.
"For patients, you know, for a lot of individuals, participating in a clinical trial is their only option," she said. "We want anybody who's facing a difficult health issue they should have that access, and they should know about what their options are. So, you know, that's where I feel like there's, there's a lot of promise going forward."
Update 10/14/2023 at 4:47 p.m.: This story was updated to correct Seema Verma's title.
View 0 Comments
Submit Correction
View Editorial & AI Guidelines